DRG uses cookies to improve your experience on this website. Some of the cookies we use are essential for parts of the website to operate. Please be aware that if you continue without changing your cookie settings, you consent to this. For more information on our use of cookies, please review our cookie policy.

Research & Reports

Searching in Biopharma (1808)

Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia | Landscape & Forecast | Disease Landscape & Forecast

Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia | Landscape & Forecast | Disease Landscape & Forecast

Thank you!

Your request has been received by DRG. A represantative will contact you shortly to provide more details on the research and data contained in this report and ensure that it will meet your current research needs.

The launch of several novel therapies, as well as multiple label expansions of premium-priced agents, will fuel significant growth of the non-Hodgkin’s lymphoma (NHL) therapy market over the ten-year forecast period. One of these novel therapies is Yescarta, the first chimeric antigen receptor (CAR) T-cell therapy; it is approved for relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) and represents a significant milestone in NHL drug development. Offsetting this market growth will be the biosimilar erosion expected for rituximab, the patient-, and market-share leader in 2017 in the NHL space, and the generic erosion of Revlimid (and, to a lesser extent, bendamustine). Untapped clinical and commercial potential remains in NHL for therapies with improved efficacy and for agents positioned in patient segments that are currently underserved.

Questions Answered:

  • Kinase inhibitors have changed the NHL treatment algorithm since their recent approval. Which other kinase inhibitors are most promising in NHL, and what patient populations will they target? What will be their impact on the NHL market?
  • Rituxan/MabThera is widely used in all NHL drug-treated populations and garners significant sales. How will market share for rituximab change over our ten-year forecast period as a result of biosimilars? Will Gazyva/Gazyvaro achieve the same status as Rituxan/MabThera within the NHL space and thus minimize the impact of biosimilar erosion of branded rituximab?
  • The NHL therapy market will experience robust growth through 2027. What factors are driving this growth? Which drug class will dominate the treatment of NHL? What new classes of agents will emerge over the ten-year forecast period, and what will be their market impact?

Scope:

Markets covered: United States, France, Germany, Italy, Spain, United Kingdom, Japan.

Primary research: 20 country-specific interviews with experts and 210 country-specific surveys with hematologist-oncologists treating NHL.

Epidemiology: Diagnosed incidence of follicular lymphoma (FL) (including transformed FL), chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), DLBCL, and mantle cell lymphoma (MCL).

Population segments in market forecast: First line, second line, and third/fourth line for FL, CLL/SLL, DLBCL, and MCL.

Emerging therapies: Phase I and II: 45 drugs; Phase III: 10 drugs; registered: 5 drugs.

Table of contents

  • Disease Landscape & Forecast
    • Key Updates
      • December 2018
      • October 2018
      • September 2018
      • June 2018
    • Market Outlook
      • Key Findings
        • Market Overview
      • Market Drivers and Constraints
        • What Factors Are Driving the Market for NHL?
        • What Factors Are Constraining the Market for NHL?
      • Segment-Specific Trends
        • First-Line CLL/SLL
        • Relapsed/Refractory CLL/SLL
        • First-Line DLBCL
        • Relapsed/Refractory DLBCL
        • First-Line FL
        • Relapsed/Refractory FL
        • First-Line MCL
        • Relapsed/Refractory MCL
    • Forecast
    • Etiology and Pathophysiology
      • Etiology and Pathophysiology
      • Risk Factors
      • Classification of NHL
        • Staging of NHL
      • Key Pathways and Drug Targets
    • Epidemiology
      • Key Findings
      • Epidemiology Populations
        • Diagnosed Incident Cases
        • De Novo DLBCL Incident Cases by Molecular Subtype
        • Transformed Incident Cases from FL to DLBCL
        • Transformed Incident Cases from CLL to DLBCL
        • Drug-Treatable Populations
        • Drug-Treated Populations
    • Current Treatment
      • Key Findings
      • Treatment Goals
      • Key Current Therapies
        • Overview
        • Monoclonal Antibodies
        • Apoptosis-Inducing Agents
        • Immunomodulatory Agents
        • Proteasome Inhibitors
        • mTOR Inhibitors
        • Kinase Inhibitors
        • Chemotherapies
        • CAR T-Cell Therapies
        • Immune Checkpoint Inhibitors
      • Medical Practice
        • Drug-Treatable Population
        • Treatment Guidelines
        • Country-Specific Treatment
    • Unmet Need Overview
      • Current and Future Attainment of Unmet Needs in NHL
    • Emerging Therapies Overview
      • Key Findings
      • Key Emerging Therapies
        • Notable Developments Among Key Emerging Therapies for NHL
        • Kinase Inhibitors
        • Monoclonal Antibodies/Antibody-Drug Conjugates
        • CAR T-Cell Therapies
        • Immune Checkpoint Inhibitors
      • Early-Phase Pipeline Analysis
        • Notable Developments in the Early-Phase Pipeline for NHL
    • Access & Reimbursement Overview
      • Region-Specific Reimbursement Practices
        • United States
        • EU5
        • Japan
      • Looking for More?
    • Methodology
      • Bottom-Up Forecasting Overview
        • Patient Populations
        • Drug- and Regimen-Specific Assumptions
      • Bottom-Up Forecasting Assumptions
        • General Sources of Data
        • General Statements About Pricing
        • Dosing, Cycles of Therapy, and Compliance
        • Generic Erosion
        • Biosimilar Erosion
        • Out-Year Forecasting
        • Emerging Therapy Prices
      • Primary Market Research
        • Experts Interviewed
    • Appendix
      • Bibliography

Already a Client? Log in to access this report.

  • Pub Date: December 2018
  • Author(s): Amy Yip, PhD; Nicole Zhang, MPH; Lade Ayodele
  • Amy Yip, is a Business Insights Analyst in the oncology team at Decision Resources Group. Prior to joining DRG, Dr. Yip worked as an analyst at GlobalData where she worked on a number of disease reports within Healthcare and Pharmaceuticals, with a particular focus on oncology. Dr. Yip obtained her doctorate in molecular medicine at the Liggins Institute, University of Auckland, where she investigated the impact of aberrant neurotrophic factor expression on hormone signaling pathways in breast cancer cells. Dr. Yip also holds a BSc (Hons) degree, with first class honors in biomedical science, awarded by the University of Auckland, and has previously worked with Novartis in their New Zealand office.

  • Nicole Zhang is an Epidemiologist at Decision Resources Group. She focuses on the epidemiology of oncology and cardiovascular disorders. She holds an from Tufts Medical School where she specialized in epidemiology and biostatistics. She also holds a in Chemistry and Statistics from Mount Holyoke College. Prior to joining Decision Resources, she worked as a research analyst at Massachusetts General Hospital where she independently managed data from food information survey conducted in Chelsea, MA. She has also worked at Massachusetts Department of Public Health where she conducted secondary research in the fields of gestational diabetes.

  • Dr. Ayodele has expertise in forecasting disease populations and is an epidemiology expert in chronic diseases including cancers and cardiovascular diseases, in both the major and emerging pharmaceutical markets. Prior to joining Decision Resources Group, she researched antiretroviral therapy funding, availability and access at the Clinton Foundation Center for Strategic HIV Operations Research. More recently, she was a Medical Innovation and Leadership fellow at Blue Cross Blue Shield of Massachusetts, where she researched and developed strategic plans on health care utilization and quality improvement. Dr. Ayodele holds a Master in Public Health degree (quantitative methods concentration) from Harvard and a medical degree from the University of Ibadan in Nigeria. She is currently pursuing a in epidemiology at Boston University School of Public Health with a focus in pharmacoepidemiology.

Purchase Report

Recent reports:
You may also be interested in: